Pearls of Wisdom: Pharmacy

- Debra Herzan, RN, BSN, OCN, CCRP
 - Alliance Clinical Trials Auditor
 - Alliance, Chicago Office





Pharmacy: Common Problems

- NCI Drug Accountability Record Form (DARF) not correctly filled out.
- Unable to track study supplied agents.
- Inadequate storage or security of study agent.



NCI Drug Accountability Record Form (DARF) not correctly filled out

 Pearl: Refer to Pharmaceutical Management Branch (PMB) website for guidelines and video tutorials:

http://ctep.cancer.gov/branches/pmb/agent_management.htm



Collection of this information is authorized under 21 CFR 312.57. The information is collected to ensure compliance with Food and Drug Administration (FDA) requirements for NCI as an IND sponsor and that investigational agents are under the control and accounted for by competent authority. The information may be disclosed to researchers for investigational purposes, sponsors of clinical trials and their company collaborators, the applicable Institutional Review Board, NCI, FDA, and the Department of Health and Human Services. Submission of this information is voluntary however, in order for you to conduct a study in accordance with relevant, current protocols, you must complete all fields.

OMB No. 0925-0613 Expires: 03/31/2016 NIH-2564

Public reporting burden for this collection of information is estimated to average 4 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0613). Do not return the completed form to this address.

National Institutes of Health National Cancer Institute Investigational Agent Accountability Record				Cancer Ther	Division of Cancer Treatment and Diagnosis Cancer Therapy Evaluation Program CONTROL RECORD SATELLITE RECORD				
Name of	Institution:				NC	Cl Protocol No.:	LLLITE KLOO	RD 🗆	
Agent Na	ame:				Dose Form and Strength:				
Protocol	Title:	3				Dis	spensing Area:		
Investiga	ator Name:			CTEP Investigator ID:					
Line No.	Date	Patient's Initials	Patient's ID No.	Dose	Quantity Dispensed Received	or	Balance Forward	Manufacturer and Lot No.	Recorder's Initials
1.									
2.									
3.				North particle de la constitución de la constitució					
4.				25 10 c					
5.					_				
6.								#	
7.				7)					
8.									



Collection of this information is authorized under 21 CFR 312.57. This information is collected to ensure compliance with Food and Drug Administration (FDA) requirements for NCI as an IND sponsor and that investigational agents are under the control and accounted for by competent authority. The information may be disclosed to researchers for investigational purposes, sponsors of clinical trials and their company collaborators, the applicable Institutional Review Board, NCI, FDA and Department of Health and Human Services. Submission of this information is voluntary, however, in order for you to conduct a study in accordance with relevant, current protocols, you must complete all fields.

Form Approved: OMB No. 0925-0613 Expires: 03/31/2016

Public reporting burden for this collection of information is estimated to average 4 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for required this burden to XIII. Project Clearance Branch, 8705 Rockledge Drive, MBC. 7974 Retheats MD 20892-7974. ATTN: PRA 4TTN: PRA 4T

Investigational Agent Accountability Record Oral agents ONLY						ledge blive, wo	National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Cancer Therapy Evaluation Program			PAGE NO. CONTROL RECORD			
Name of Institution:						Investigator Name:				CTEP Investigato		estigator ID:	
Protocol Title:						NCI Protocol No: Local Protocol No:			Dispensing Area:				
Agent Name:						Dose Form and Strength:				Bottle size (e.g., # tablets/bottle):			
Line No.	Date	Patient's Initials	Patient's ID No.	Dose	Quanti Dispense Receiv	ed or	ance Forward Balance	Manufacturer and Lot No.	Recorder's Initials	Expiration Date (if available)	Date Patient Returned	Quantity Patient Returned	Recorder's Initials
1.													
2. 3.	· · · · · · · · · · · · · · · · · · ·											•	
4.													
5.													
6.													
7. 8.													
9.													
10.	- /				-								
<u>11.</u> 12.													
13.													
14.													
<u>15.</u> 16.					-								1 10
10.													

Unable to track study supplied agents

Pearl: Keep all records!



Transfer Investigational Agent Form

This form is to be used for an intra-institutional transfer, one transfer/form.

Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health

TRANSFER FROM:										
Investigator transferring age	CTEP Investigator ID:		Date of transfer:							
Dr.										
Name of institution:										
Street Address:		City:		State:		Zip Code:				
Reason for transfer requ	est: Protocol closed/co	mplete Unused	d agent obta	ained for Special Exception	on Agent	has short dat	ting Other*	•		
TRANSFER TO:						(**Require	s verbal clarification	on with PMB before approval)		
Investigator receiving agent	•			CTEP Investigator ID:						
Dr.										
The following PMB-supp	lied agent for NCI-approve	d protocol is being	transferred	to NCI-approved protocol	l:					
Received on NCI Protocol Number	Transferred to NCI Protocol Number	NSC Number		Agent Name Strength an		and Formulation Quan		Manufacturer and Lot Number		
Authorized Signature (Investigator or Designee)						Return form to: Pharmaceutical Management Branch, CTEP, DCTD NCI Shady Grove Room 5W228, MSC 9725				
Printed Name		9609 Medical Center Drive Bethesda, MD 20892-9725								
Telephone Number		PMBAfterhours@mail.nih.gov								
Email Address				FAX: 240	0-276-789	3				

See http://ctep.cancer.gov/branches/pmb/agent management.htm for further information.

All requested information MUST be supplied for form to be valid.

NIH-986 (REV. 2/97)		03/09	
National Institutes of Health Division of Cancer Treatment and Diagnosis	Address: (Including Institution)	FOR NCI USE ONLY	
National Cancer Institute Cancer Therapy Evaluation Program		Return, No.:	
Return Drug List			
Return only agents <u>supplied by</u> :			
CTEP, DCTD, National Cancer Institute		Signature of Authorizing Official:	
OTET, DOTE, National Cancer institute			
The control list of helicity and and her foreign and foreign and her			
The agents listed below were ordered by (one investigator per form only):		ing y	
Dr.		Date of Authorization.	
	Check here if returned receipt should be mailed to the		
NCI Investigator No.:	above address, OR fill in a fax number below	, 10 T S A	
NO. D. Stren	with 9 Formatilation	Container	
NOC I NOT TOLOGO	ify vials, capsules, or tablets) Lot Number (or Patient ID for Blinded Trial) Manufacturer (Specify whole or partial containers)	Number Action	
	(auxis)		
Reason for return: Lot expired Protocol closed/complete IND withdrawn/	nactivated Patient cross over Patient expired/went off treatment Unsuitable		
2		105.7	
Reason for return: Lot expired Protocol closed/complete IND withdrawn/	nactivated Patient cross over Patient expired/went off treatment Unsuitable		
3			
Reason for return: Lot expired Protocol closed/complete IND withdrawn/	nactivated Patient cross over Patient expired/went off treatment Unsuitable		
	nactivated Patient cross over Patient expired/went off treatment Unsuitable		
Reason for return: Lot expired Protocol closed/complete IND withdrawn/	nactivated Patient cross over Patient expired/went off treatment Unsuitable	9.004.28	
REPOSITORY COMMENTS			
		en si	
	Date Received:	la l	
	Date Necessed.		
INSTRUCTIONS:			
Properly complete all sections to receive credit for the return.	Pack the agent(s) well to minimize breakage and leakage.		
2. Type all information-one item, lot, or protocol per line.	6. All agents may be returned via room temperature		
3. DO NOT mark in shaded areas.	7. Enclose the completed list with the agent(s) and return to:		
4. Investigator signature or signature of individual preparing this form:	NCI Climical Danasitani	: To obtain a return	
4. Investigator signature or signature of mulvidual preparing this form.	receipt by fax, provi	de your number in the	
	627 Lofstrand Lane space below.	,	
Circulum / District Name	Rockville, MD 20850		
Signature / Printed Name Date	'		
	Attn: Returns		
Title Phone No.			

Inadequate storage or security of study agent

 Pearl: Refer to PMB Policy & guidelines for Accountability and Storage of Investigational Agents



Pearls of Wisdom: Pharmacy

Please save questions for the panel at the end of the presentations.

